MX2020002809A - Genes rep de aav inducibles. - Google Patents

Genes rep de aav inducibles.

Info

Publication number
MX2020002809A
MX2020002809A MX2020002809A MX2020002809A MX2020002809A MX 2020002809 A MX2020002809 A MX 2020002809A MX 2020002809 A MX2020002809 A MX 2020002809A MX 2020002809 A MX2020002809 A MX 2020002809A MX 2020002809 A MX2020002809 A MX 2020002809A
Authority
MX
Mexico
Prior art keywords
aav
aav rep
rep genes
rep78
rep68
Prior art date
Application number
MX2020002809A
Other languages
English (en)
Inventor
Silke Wissing
Nicole Faust
Kerstin Hein
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Publication of MX2020002809A publication Critical patent/MX2020002809A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a células huésped que comprenden un ácido nucleico que codifica las proteínas Rep78 y Rep68 del virus adenoasociado (AAV), en donde el promotor interno de AAV p19 ha sido inactivado por una o más mutaciones que mantienen la funcionalidad de dichas proteínas Rep78 y Rep68. La presente invención se refiere además a ácidos nucleicos respectivos y vectores que comprenden los mismos, así como a métodos respectivos para la producción de AAV.
MX2020002809A 2017-09-19 2018-09-18 Genes rep de aav inducibles. MX2020002809A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17001562.2A EP3456822A1 (en) 2017-09-19 2017-09-19 Inducible aav rep genes
PCT/EP2018/075158 WO2019057691A1 (en) 2017-09-19 2018-09-18 INDAVTIBLE AAV GEN GENES

Publications (1)

Publication Number Publication Date
MX2020002809A true MX2020002809A (es) 2020-10-12

Family

ID=59930156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002809A MX2020002809A (es) 2017-09-19 2018-09-18 Genes rep de aav inducibles.

Country Status (13)

Country Link
US (3) US11685932B2 (es)
EP (2) EP3456822A1 (es)
JP (1) JP7254777B2 (es)
KR (2) KR102706871B1 (es)
CN (1) CN111108197A (es)
AU (2) AU2018337571B2 (es)
BR (1) BR112020005404A2 (es)
CA (1) CA3073622A1 (es)
IL (1) IL273176B2 (es)
MX (1) MX2020002809A (es)
SG (1) SG11202000443SA (es)
WO (1) WO2019057691A1 (es)
ZA (1) ZA202000862B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041322A1 (en) 2019-08-23 2021-03-04 Lonza Walkersville, Inc. Methods and constructs for production of lentiviral vector
CN115298316B (zh) * 2020-02-04 2025-02-14 牛津遗传学有限公司 用于制备腺相关病毒载体的方法
US12054738B2 (en) 2020-07-30 2024-08-06 Shape Therapeutics Inc. Stable cell lines for inducible production of rAAV virions
CA3197730A1 (en) 2020-10-15 2022-04-21 F. Hoffman-La Roche Ag Nucleic acid constructs for va rna transcription
EP4006141A1 (en) * 2020-11-25 2022-06-01 CEVEC Pharmaceuticals GmbH Method for the production of aav
CN116829725A (zh) * 2021-02-12 2023-09-29 富士胶片株式会社 用于产生腺相关病毒的试剂盒及其利用
CN117529491A (zh) * 2021-04-23 2024-02-06 阿西莫夫公司 用于慢病毒载体产生的稳定产生系统
TW202323529A (zh) 2021-10-18 2023-06-16 美商再生元醫藥公司 包括腺病毒相關病毒聚核苷酸的真核細胞
IL312487A (en) * 2021-11-09 2024-07-01 Asimov Inc Stable production systems for adeno-associated virus vector production
JPWO2023171698A1 (es) 2022-03-08 2023-09-14
CN116064672B (zh) * 2022-09-15 2025-02-14 思鹏生物科技(苏州)有限公司 利用ires基因提升aav包装效率的方法及其功能基因
WO2024121778A1 (en) * 2022-12-09 2024-06-13 Pfizer Inc. Improved rep genes for recombinant aav production
JPWO2024143440A1 (es) 2022-12-28 2024-07-04
CN121794392A (zh) * 2023-09-06 2026-04-03 学谱治疗公司 用于产生aav的rep启动子
WO2025206262A1 (ja) * 2024-03-29 2025-10-02 富士フイルム株式会社 変異ＲＥＰタンパク質、ｒｅｐ遺伝子およびその利用
CN118460545B (zh) * 2024-07-08 2025-02-11 凌意(杭州)生物科技有限公司 一种诱导型表达Rep多肽的表达框

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0668Y2 (ja) * 1987-04-24 1994-01-05 ブラザー工業株式会社 ポケツト折機の照明装置
WO1997020943A1 (en) 1995-12-01 1997-06-12 Introgene B.V. Regulated protein expression in stably transfected mammalian cells
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
AU2002367943A1 (en) * 2001-12-18 2003-12-22 University Of North Carolina At Chapel Hill Improved reagents and methods for producing parvoviruses
CA2853482C (en) * 2011-10-28 2020-05-19 Joshua Grieger Cell line for production of adeno-associated virus
CA3127629A1 (en) 2019-01-25 2020-07-30 Biogen Ma Inc. Seed culture process for aav production
EP3962536A1 (en) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors

Also Published As

Publication number Publication date
WO2019057691A1 (en) 2019-03-28
US20200277628A1 (en) 2020-09-03
EP3456822A1 (en) 2019-03-20
US12060569B2 (en) 2024-08-13
IL273176B1 (en) 2025-01-01
RU2020111459A3 (es) 2021-11-29
RU2020111459A (ru) 2021-10-20
KR20240137720A (ko) 2024-09-20
JP7254777B2 (ja) 2023-04-10
JP2020536505A (ja) 2020-12-17
AU2025203266A1 (en) 2025-05-29
AU2018337571A1 (en) 2020-01-30
AU2018337571B2 (en) 2025-03-13
BR112020005404A2 (pt) 2020-09-29
IL273176B2 (en) 2025-05-01
KR102706871B1 (ko) 2024-09-20
SG11202000443SA (en) 2020-02-27
CA3073622A1 (en) 2019-03-28
IL273176A (en) 2020-04-30
KR20200052283A (ko) 2020-05-14
US11685932B2 (en) 2023-06-27
EP3649239A1 (en) 2020-05-13
CN111108197A (zh) 2020-05-05
US20250011813A1 (en) 2025-01-09
ZA202000862B (en) 2021-02-24
US20230348936A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
MX2020002809A (es) Genes rep de aav inducibles.
CO2018000134A2 (es) Factor ix modificado, y composiciones para la transferencia de genes a células, órganos y tejidos
CL2023003010A1 (es) Novedosas proteínas de la cápside del virus adenoasociado
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
MX2020004145A (es) Variantes de desoxirribonucleasa (dnasa).
CL2018003196A1 (es) Cápsides variantes de virus adenoasociados y métodos de uso de estas.
CL2017002820A1 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
PE20211419A1 (es) Vectores virales recombinantes y acidos nucleicos para producirlos
MX2018012376A (es) Sistemas de replicón de arterivirus recombinantes y usos de estos.
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
MX2016010649A (es) Vector de virus adeno-asociado.
CL2017003096A1 (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis
HUE062774T2 (hu) Módosított rAAV kapszidfehérje génterápiához
CL2016000502A1 (es) Vectores mejorados del factor viii del virus adeno-asociado de menos de 5,0 kb de longitud, que producen un polipéptido del factor viii funcionalmente activo para el tratamiento de la hemofilia a.
CR20160555A (es) Vectores de aav para la terapia génica de la retina y el snc
CL2019000033A1 (es) Variantes de xilanasa y polinucleótidos que las codifican.
MX2017005672A (es) Erradicacion guiada de arn de virus jc mano y otros poliomavirus.
BR102014006322B8 (pt) 4-amino-6-picolinatos(heterocílicos) e 6-amino-2-pirimidina-(heterocíclica)-4-carboxilatos, e processo para controle de vegetação indesejada
MX366343B (es) Terapia genetica.
AR100419A1 (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
MX2017003426A (es) Vectores virales adeno-asociados para tratar glaucoma de miocilina (myoc).
MX2018010842A (es) Expresion mediada por el virus adeno-asociado (aav) usando un promotor y pontenciador sintetico.
AR099837A1 (es) Terapia génica para la retinitis pigmentaria